Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by AntibeTribeon Feb 27, 2020 5:35pm

101 Views

Post# 30743826

RE:RE:RE:.?.....?.Querie

From the article: "TMX Corp. ordered the halt a little before 2 p.m. ET on Thursday, citing a "problem with order entry" on the main index, the TSX Venture Exchange and the alternative Alpha Exchange. The outage appears to have also affected the Montreal Exchange, which processes derivatives such as stock options and commodity futures contracts."

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale